Company Overview of Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products to treat patients with severe inherited orphan diseases in ophthalmology in the United States. The company’s lead product candidates include treatments for X-linked retinoschisis, achromatopsia, and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye caused by mutations in single genes. It is also developing adeno-associated virus based gene therapies for the treatment of rare eye diseases; and a product candidate for treatment of alpha-1 antitrypsin deficiency for which it has conducted preclinical proof-of-concept studies and Phase I and Phase II clinic...
11801 Research Drive
Alachua, FL 32615
Founded in 1999
Key Executives for Applied Genetic Technologies Corporation
Chief Executive Officer, President and Director
Total Annual Compensation: $400.0K
Chief Financial Officer
Total Annual Compensation: $300.0K
Chief Medical Officer and Vice President
Total Annual Compensation: $350.0K
Chief Business Officer and Vice President
Total Annual Compensation: $127.1K
Executive Director of Process Development
Total Annual Compensation: $122.4K
Compensation as of Fiscal Year 2015.
Applied Genetic Technologies Corporation Key Developments
Applied Genetic Technologies Corporation Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat Achromatopsia
Nov 23 15
Applied Genetic Technologies Corporation announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its gene therapy product candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene. The company presented early preclinical findings in a naturally occurring dog model of the CNGB3 form of the disease, and previously received orphan drug designation from the FDA and the EMA for its investigational gene therapy product for the treatment of an additional variant of achromatopsia caused by mutations in the CNGB3 gene. More recent studies conducted by company's collaborators showed that in sheep affected by achromatopsia caused by mutations in the CNGA3 gene, delivery of an AAV vector carrying a normal copy of CNGA3 restored vision, as measured by the ability to navigate an obstacle maze. Orphan drug designation, covered by the U.S. Orphan Drug Act of 1983, is granted to drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 individuals. Products receiving orphan drug designation are eligible to receive market exclusivity for a period of seven years, an accelerated regulatory review process, an exemption from certain taxes and user fees and additional clinical support from FDA.
Applied Genetic Technologies Corporation Presents at Credit Suisse 24th Annual Healthcare Conference, Nov-11-2015 10:00 AM
Nov 6 15
Applied Genetic Technologies Corporation Presents at Credit Suisse 24th Annual Healthcare Conference, Nov-11-2015 10:00 AM. Venue: The Phoenician Hotel, Scottsdale, Arizona, United States. Speakers: Lawrence E. Bullock, Chief Financial Officer.
Applied Genetic Technologies Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2015
Nov 5 15
Applied Genetic Technologies Corporation reported unaudited consolidated earnings results for the first quarter ended September 30, 2015. Total revenue for the three months ended September 30, 2015 was $11.1 million compared to $705,000 generated during the same period in 2014. The increase was largely attributable to the recognition as revenue of a portion of the nonrefundable upfront fees received in August 2015 by the company under its collaboration agreement with Biogen, and milestone revenue of $5.0 million that was recorded during the quarter following achievement of a patient enrollment-based milestone under that collaboration. For the three months ended September 30, 2015, the company incurred a net loss of $9.1 million, up from a loss of $5.4 million during the same period in 2014. Loss from operations was $9,213,000 against $5,381,000 a year ago. Net loss per share, basic and diluted was $0.53 against $0.34 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 2, 2015